You searched for prescription-drugs | Page 49 of 179

7 in 10 Medicare Beneficiaries Report That They Did Not Compare Their Coverage Options During a Recent Open Enrollment Period

Oct 13, 2021

News Release

With the Medicare open enrollment period set to begin October 15, a new KFF analysis finds that 7 in 10 beneficiaries (71%) say that they didn’t compare their coverage options during a recent open enrollment season. Twenty-nine percent said they did compare Medicare plans. But not shopping around can have a big impact on enrollees’ coverage and costs. The Centers for Medicare & Medicaid Services (CMS) recommends that beneficiaries review and compare Medicare plans each…

Section 1115 Waiver Watch: A Look at the Use of Contingency Management to Address Stimulant Use Disorder

Jan 9, 2025

Policy Watch

Contingency management is an evidence-based psychosocial intervention that uses motivational incentives, such as vouchers or gift cards, to encourage recovery behaviors like stimulant abstinence and treatment session (e.g., cognitive behavioral therapy, group therapy) attendance. The Biden administration has approved five state contingency management waivers (California, Delaware, Hawaii, Montana, and Washington); two additional state contingency management requests are currently pending federal review.

Benchmark Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023; Workers Contribute $6,575 on Average Now, But Potentially More Soon

Oct 18, 2023

News Release

Amid rising inflation, annual family premiums for employer-sponsored health insurance climbed 7% on average this year to reach $23,968, a sharp departure from virtually no growth in premiums last year, the 2023 benchmark KFF Employer Health Benefits Survey finds. On average, workers this year contribute $6,575 annually toward the cost of family premium, up nearly $500 from 2022, with employers paying the rest. Future increases may be on the horizon, as nearly a quarter (23%)…

Drug Price Negotiation Doesn’t Mean the Government Will Restrict Access to Medicines

Oct 7, 2021

Policy Watch

This policy watch evaluates the pharmaceutical industry's claims that allowing the federal government to negotiate drug prices would restrict access to medications in Medicare. It explains what the current proposal to allow drug price negotiation would and wouldn't do.

FAQs on Medicare Coverage and Costs Related to COVID-19 Testing and Treatment

Feb 3, 2022

Issue Brief

These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries, including questions related to out-of-pocket costs, the COVID-19 vaccine, telehealth, extended supplies of medication, skilled nursing facility stays, and issues for people in private Medicare Advantage plans.

Mail Order Sales of Prescriptions Drugs by Payer

Mar 5, 2020

State Health Facts Indicator

Number of Mail Order Prescriptions Drugs by Payer

Mar 5, 2020

State Health Facts Indicator

Are the Tradeoffs from Prior Authorization Worth It?

Mar 16, 2026

From Drew Altman

In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs.

Help with Medicare Premium and Cost-Sharing Assistance Varies by State

Apr 20, 2022

Issue Brief

This data note provides an overview of programs that help beneficiaries with modest incomes with their Medicare costs, including the Medicare Savings Programs and the Part D Low-Income Subsidy, and highlights findings from corresponding state-level profiles of eligibility and enrollment.

Interest in Using Over-the-Counter Oral Contraceptive Pills: Findings from the 2022 KFF Women’s Health Survey

Nov 3, 2022

Issue Brief

This brief presents data from the 2022 KFF Women’s Health Survey about reproductive age (18-49) females’ preferences for an over-the-counter contraceptive pill (N = 4,088).

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

Search

Filter